ArticleEuropean journal of orthopaedic surgery & traumatology : orthopedie traumatologie2026
Is direct anterior approach associated with a compromise of femoral stem survival after total hip arthroplasty? A regional registry-based analysis.
Article in European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe direct anterior approach (DAA) for uncemented total hip arthroplasty (THA) has been advocated for early functional recovery, yet concerns persist regarding its influence on femoral component survival. We analysed a large regional registry to compare implant survivorship and the risk of aseptic femoral loosening between DAA and conventional direct lateral/posterolateral (DL-PL) approaches. MATERIALS AND
methodsWe conducted a retrospective cohort study of 30,753 primary uncemented THAs recorded in the Emilia-Romagna Prosthetic Implant Registry (RIPO) from January 2009 through December 2021. Procedures were classified by surgical approach as DAA (n = 7,663) or DL-PL (n = 23,090). Demographic variables, implant characteristics (including stem length), and reasons for revision were extracted. Kaplan-Meier analysis estimated cumulative survivorship for any-cause revision and for revision due to aseptic loosening; group differences were assessed with the log-rank test. Multivariable Cox proportional hazards models, stratified by age (< 65 vs ≥ 65 years) and adjusted for sex and stem length, evaluated the independent effect of surgical approach on aseptic revision risk. Median follow-up was 4.6 years (IQR 2.3-7.65).
resultsPatients undergoing DAA were slightly younger (mean 67.6 ± 10.4 vs 69.6 ± 9.8 years; p 0.001), less frequently obese (21.5% vs 28.7%; p < 0.001), and more often received short femoral stems (58.6% vs 24.8%; p < 0.001). DAA utilization increased markedly over the study period. Twelve-year cumulative survivorship for all-cause revision was high and similar between groups (DAA 95.6%, 95% CI 94.5-96.7; DL-PL 94.9%, 95% CI 94.4-95.5; log-rank p = 0.554). For aseptic loosening, 12-year survivorship was also comparable (DAA 98.9% vs DL-PL 98.4%; p = 0.562). In age-stratified adjusted Cox models, surgical approach was not an independent predictor of aseptic revision (age < 65: HR 0.81, 95% CI 0.46-1.44; age ≥ 65: HR 1.32, 95% CI 0.77-2.26).
conclusionsIn this large registry-based series, the DAA was not associated with inferior long-term implant survivorship or a higher risk of aseptic femoral loosening compared with DL-PL approaches after adjustment for patient and implant factors. These findings indicate that, at a population level and with appropriate case and implant selection, DAA yields mechanical outcomes comparable to traditional approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.